Chugai Pharma announces 48-week NIHONBASHI phase III study results presented at JRVS meeting show that Vabysmo sustained vision improvements in Japanese patients with angioid streaks ...

AI is advancing our understanding of the complexities of age-related macular degeneration, according to a presenter.

European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ...

Caregen to release US phase 1 results for eyedrop CG-P5 against Eylea Caregen to reveal delayed phase 1 eyedrop data for ...

Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for BYOOVIZ (ranibizumab) pre-filled syringe (PFS) PFS presentation to become ...

About one-third of highly myopic eyes with myopic macular neovascularization develop early atrophy within 2 years, a study shows.

A retinal implant made big news with recent headlines saying it can restore vision lost to geographic atrophy. Here, experts ...

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis pigmentosa and Stargardt disease.

Tinlarebant is a novel oral therapy designed to reduce the build-up of bisretinoids, vitamin A-based toxins that lead to retinal complications in STGD1.